CDK Inhibitor Combinations for BRAF-Resistant Melanoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Metastatic melanoma and BRAF mutant melanoma are difficult to treat effectively with existing therapies, leading to poor response rates and limited progression-free survival, with drug resistance and tumor recurrence being significant challenges.
Innovation Solution
A pharmaceutical combination comprising a CDK inhibitor represented by a compound of formula I or its pharmaceutically acceptable salt, in combination with a BRAF or MEK inhibitor, is administered to treat melanoma, leveraging synergistic effects to enhance therapeutic efficacy and prevent drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRAF inhibitors are used to treat BRAF mutant melanoma, then tumor shrinkage is achieved, but drug resistance develops and progression-free survival is limited to 5-7 months
Solution Approach 1:
The patent combines BRAF inhibitors with MEK inhibitors in a dual-targeted therapy approach. This merging of two different inhibitor types targets multiple points in the MAPK signaling pathway simultaneously, preventing the development of drug resistance and extending progression-free survival beyond what single-agent BRAF inhibition can achieve.
Solution Approach 2:
The invention uses a composite therapeutic regimen comprising two distinct pharmacological agents (BRAF inhibitor and MEK inhibitor) that work synergistically. This composite approach addresses the limitation of single-agent therapy by creating a multi-mechanism treatment that overcomes drug resistance through complementary modes of action.
2Ease of operation
If conventional chemotherapy drugs (dacarbazine, temozolomide, fotemustine, carboplatin) are used for metastatic melanoma, then treatment is provided, but response rates are poor (7-12%) and overall survival is limited (5-8 months)
Solution Approach 1:
The patent fundamentally changes the therapeutic parameter from conventional chemotherapy to targeted kinase inhibition. By identifying and targeting specific molecular parameters (BRAF and MEK kinases) that are dysregulated in melanoma, the treatment achieves significantly higher response rates and improved survival outcomes compared to non-specific chemotherapy agents.
Solution Approach 2:
The invention introduces targeted kinase inhibitors as intermediary agents that specifically block the aberrant signaling pathways in melanoma cells. These intermediaries (BRAF and MEK inhibitors) act as precise mediators between the drug and the disease mechanism, providing more effective treatment than conventional chemotherapy by interfering with the specific molecular intermediaries driving tumor growth.
3Productivity
If single-agent BRAF inhibition is used, then initial tumor response is achieved, but resistance develops rapidly limiting long-term efficacy
Solution Approach 1:
The patent employs preliminary action by adding MEK inhibition to the regimen before resistance to BRAF inhibition can develop. This preemptive dual-targeting strategy prevents the activation of compensatory survival pathways that would otherwise lead to drug resistance, thereby maintaining long-term treatment efficacy.
Solution Approach 2:
The combination therapy creates a feedback-controlled system where inhibition of both BRAF and MEK provides mutual reinforcement. The MEK inhibitor prevents feedback activation of the pathway downstream of BRAF, while BRAF inhibition upstream complements the effect, creating a robust feedback loop that sustains therapeutic response and prevents resistance.
Data Source
AI summary
The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.